EX-99.1
2
ex99106-09x2020.htm
EX-99.1
Document
Exhibit 99.1
Supernus Completes Acquisition of CNS Portfolio from US WorldMeds
Creates leading CNS portfolio with five marketed products, two product candidates in late-stage development, and robust pipeline
ROCKVILLE, Md., June 9, 2020 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced the closing of the acquisition of the CNS portfolio of US WorldMeds, a privately-held biopharmaceutical company. This transaction builds on Supernus' experience in CNS diseases and expands its marketing and development efforts into Parkinson's disease.
"This acquisition significantly expands our business in CNS and increases and diversifies our revenue and earnings streams, while continuing to maintain a strong balance sheet", said Jack Khattar, President and CEO of Supernus. "We welcome our US WorldMeds' colleagues who are joining Supernus and look forward to working with them on building our leadership position in CNS across numerous diseases".
For additional details relating to the acquisition, please see the press release issued by Supernus on April 28, 2020 announcing the acquisition.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy, Apokyn® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson's disease (PD), Myobloc® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults, and Xadago® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.
APOKYN Pen and apomorphine infusion pump product candidate are under a license from Britannia Pharmaceuticals Limited
XADAGO is under a license from Zambon S.p.A
All trademarks are the property of their respective owners
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information, but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company's ability to successfully incorporate and integrate the acquired products and product candidate, technologies, sales force and organization into its current infrastructure, the Company's ability to achieve the anticipated revenues and benefits from the acquired products; the Company's ability to sustain and increase its profitability; the Company's ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's ability to increase the number of prescriptions written for each of its products; the Company's ability to increase its net revenue; the Company's ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company's product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidates; the Company's ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements;
the therapeutic benefits, effectiveness and safety of the Company's product candidates; the accuracy of the Company's estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company's ability to increase its manufacturing capabilities for its products and product candidates; the Company's projected markets and growth in markets; the Company's product formulations and patient needs and potential funding sources; the Company's staffing needs; and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
CONTACTS:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
Westwicke, an ICR Company
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com

EX - 99 . 1 2 ex99106 - 09x2020 . htm EX - 99 . 1 Document Exhibit 99 . 1 Supernus Completes Acquisition of CNS Portfolio from US WorldMeds Creates leading CNS portfolio with five marketed products , two product candidates in late - stage development , and robust pipeline ROCKVILLE , Md . , June 9 , 2020 - Supernus Pharmaceuticals , Inc . ( Nasdaq : SUPN ) , a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ( CNS ) diseases , today announced the closing of the acquisition of the CNS portfolio of US WorldMeds , a privately - held biopharmaceutical company . This transaction builds on Supernus ' experience in CNS diseases and expands its marketing and development efforts into Parkinson ' s disease . " This acquisition significantly expands our business in CNS and increases and diversifies our revenue and earnings streams , while continuing to maintain a strong balance sheet " , said Jack Khattar , President and CEO of Supernus . " We welcome our US WorldMeds ' colleagues who are joining Supernus and look forward to working with them on building our leadership position in CNS across numerous diseases " . For additional details relating to the acquisition , please see the press release issued by Supernus on April 28 , 2020 announcing the acquisition . About Supernus Pharmaceuticals , Inc . Supernus Pharmaceuticals , Inc . is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ( CNS ) diseases . The Company markets Trokendi XR ® ( extended - release topiramate ) for the prophylaxis of migraine and the treatment of epilepsy , Oxtellar XR ® ( extended - release oxcarbazepine ) for the treatment of epilepsy , Apokyn ® ( apomorphine hydrochloride injection ) for the acute treatment of hypo mobility in advanced Parkinson ' s disease ( PD ) , Myobloc ® ( rimabotulinumtoxinB ) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults , and Xadago ® ( safinamide ) as an adjunctive treatment to levodopa / carbidopa in PD patients with hypo mobility . The Company is also developing several product candidates to address large market opportunities in the CNS market , including SPN - 812 for the treatment of ADHD , apomorphine infusion pump for hypo mobility in PD , SPN - 820 ( NV - 5138 ) for treatment - resistant depression , and SPN - 817 for the treatment of epilepsy . APOKYN Pen and apomorphine infusion pump product candidate are under a license from Britannia Pharmaceuticals Limited XADAGO is under a license from Zambon S . p . A All trademarks are the property of their respective owners Forward - Looking Statements This press release includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . These statements do not convey historical information , but relate to predicted or potential future events that are based upon management 's current expectations . These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements . In addition to the factors mentioned in this press release , such risks and uncertainties include , but are not limited to , the Company 's ability to successfully incorporate and integrate the acquired products and product candidate , technologies , sales force and organization into its current infrastructure , the Company 's ability to achieve the anticipated revenues and benefits from the acquired products ; the Company 's ability to sustain and increase its profitability ; the Company 's ability to raise sufficient capital to fully implement its corporate strategy ; the implementation of the Company 's corporate strategy ; the Company 's future financial performance and projected expenditures ; the Company 's ability to increase the number of prescriptions written for each of its products ; the Company 's ability to increase its net revenue ; the Company 's ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies ; the Company 's product research and development activities , including the timing and progress of the Company 's clinical trials , and projected expenditures ; the Company 's ability to receive , and the timing of any receipt of , regulatory approvals to develop and commercialize the Company 's product candidates ; the Company 's ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others ; the Company 's expectations regarding federal , state and foreign regulatory requirements ; the therapeutic benefits , effectiveness and safety of the Company 's product candidates ; the accuracy of the Company 's estimates of the size and characteristics of the markets that may be addressed by its product candidates ; the Company 's ability to increase its manufacturing capabilities for its products and product candidates ; the Company 's projected markets and growth in markets ; the Company 's product formulations and patient needs and potential funding sources ; the Company 's staffing needs ; and other risk factors set forth from time to time in the Company 's filings with the Securities and Exchange Commission made pursuant to Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 , as amended . The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events . CONTACTS : Jack A . Khattar , President and CEO Gregory S . Patrick , Senior Vice President and CFO Supernus Pharmaceuticals , Inc . Tel : ( 301 ) 838 - 2591 or INVESTOR CONTACT : Peter Vozzo Westwicke , an ICR Company Office : ( 443 ) 213 - 0505 Mobile : ( 443 ) 377 - 4767 Email : peter.vozzo@westwicke.com
O O O O O O O O O O O O O O O O O O O O O B-Parties.BUYING_COMPANY O O O O O O B-Parties.SELLING_COMPANY I-Parties.SELLING_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B-Parties.SELLING_COMPANY I-Parties.SELLING_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O